Pediatr Allergy Immunol:lgE敏感和鼻炎对炎症生物标记和肺功能的影响

2018-11-08 AlexYang MedSci原创

过敏性和非过敏性鼻炎与更差的哮喘控制相关。然而,lgE敏感和/或鼻炎是怎样与肺功能相关的还不清楚。最近,有研究人员评估了鼻炎和敏感对肺功能的影响,包括了患有或不患有哮喘患者的气道系统周边和炎症生物标记情况。研究人员将哮喘、鼻炎和敏感组合的小组与健康的对照进行了比较。研究发现,在只患有哮喘(调整后平均差-2.8%-单位(95% CI -4.7;-1.0), p<0.01))、哮喘和敏感(-2.

过敏性和非过敏性鼻炎与更差的哮喘控制相关。然而,lgE敏感和/或鼻炎是怎样与肺功能相关的还不清楚。最近,有研究人员评估了鼻炎和敏感对肺功能的影响,包括了患有或不患有哮喘患者的气道系统周边和炎症生物标记情况。

研究人员将哮喘、鼻炎和敏感组合的小组与健康的对照进行了比较。研究发现,在只患有哮喘(调整后平均差-2.8%-单位(95% CI -4.7;-1.0), p<0.01))、哮喘和敏感(-2.0(-3.9;-0.2), p<0.05)和同时患有哮喘、敏感和鼻炎(-2.5(-3.6;-1.4), p<0.001)患者中FEV1/FVC水平更低。另外,外周呼吸道抗性R5-20在哮喘和敏感组中更高(调整后平均差94.9 Pa·L-1 ·s-1 (95% CI 60.4;129.3),p<0.001),同时患有哮喘、敏感和鼻炎的患者组中为(36.9(15.0;58.8), p<0.01)。另外,这些小组中FeNO的水平和嗜酸性粒细胞水平均增加。

最后,研究人员指出,不考虑鼻炎状态,他们在过敏性哮喘患者中发现了外周呼吸道障碍的迹象和炎症生物标记水平的增加情况。尽管FEV1/FVC的水平减少,在非敏感哮喘青少年中并没有观察到外周气到的接触。研究人员还指出,在青少年过敏性哮喘中,小气道疾病与嗜酸性粒细胞炎症相关。

原始出处:

Hallberg J, Ballardini N, Almqvist C et al. Impact of IgE sensitization and rhinitis on inflammatory biomarkers and lung function in adolescents with and without asthma. Pediatr Allergy Immunol. 20 Oct 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1638850, encodeId=2e33163885050, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Mar 29 22:51:00 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727708, encodeId=d9fa1e27708f6, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Jul 15 19:51:00 CST 2019, time=2019-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329171, encodeId=90ea13291e160, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sat Nov 10 03:51:00 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345382, encodeId=57e01345382e1, content=<a href='/topic/show?id=8907693e0fa' target=_blank style='color:#2F92EE;'>#生物标记#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69370, encryptionId=8907693e0fa, topicName=生物标记)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=278f2500221, createdName=12498fa0m11暂无昵称, createdTime=Sat Nov 10 03:51:00 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539212, encodeId=0fd015392124e, content=<a href='/topic/show?id=6505108534a' target=_blank style='color:#2F92EE;'>#lgE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10853, encryptionId=6505108534a, topicName=lgE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=beb613117181, createdName=HNYYM, createdTime=Sat Nov 10 03:51:00 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351954, encodeId=16f33519548c, content=好文,值得点赞!认真学习了,把经验应用于实践,为患者解除病痛。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Thu Nov 08 14:19:05 CST 2018, time=2018-11-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1638850, encodeId=2e33163885050, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Mar 29 22:51:00 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727708, encodeId=d9fa1e27708f6, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Jul 15 19:51:00 CST 2019, time=2019-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329171, encodeId=90ea13291e160, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sat Nov 10 03:51:00 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345382, encodeId=57e01345382e1, content=<a href='/topic/show?id=8907693e0fa' target=_blank style='color:#2F92EE;'>#生物标记#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69370, encryptionId=8907693e0fa, topicName=生物标记)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=278f2500221, createdName=12498fa0m11暂无昵称, createdTime=Sat Nov 10 03:51:00 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539212, encodeId=0fd015392124e, content=<a href='/topic/show?id=6505108534a' target=_blank style='color:#2F92EE;'>#lgE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10853, encryptionId=6505108534a, topicName=lgE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=beb613117181, createdName=HNYYM, createdTime=Sat Nov 10 03:51:00 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351954, encodeId=16f33519548c, content=好文,值得点赞!认真学习了,把经验应用于实践,为患者解除病痛。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Thu Nov 08 14:19:05 CST 2018, time=2018-11-08, status=1, ipAttribution=)]
    2019-07-15 feather89
  3. [GetPortalCommentsPageByObjectIdResponse(id=1638850, encodeId=2e33163885050, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Mar 29 22:51:00 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727708, encodeId=d9fa1e27708f6, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Jul 15 19:51:00 CST 2019, time=2019-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329171, encodeId=90ea13291e160, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sat Nov 10 03:51:00 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345382, encodeId=57e01345382e1, content=<a href='/topic/show?id=8907693e0fa' target=_blank style='color:#2F92EE;'>#生物标记#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69370, encryptionId=8907693e0fa, topicName=生物标记)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=278f2500221, createdName=12498fa0m11暂无昵称, createdTime=Sat Nov 10 03:51:00 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539212, encodeId=0fd015392124e, content=<a href='/topic/show?id=6505108534a' target=_blank style='color:#2F92EE;'>#lgE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10853, encryptionId=6505108534a, topicName=lgE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=beb613117181, createdName=HNYYM, createdTime=Sat Nov 10 03:51:00 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351954, encodeId=16f33519548c, content=好文,值得点赞!认真学习了,把经验应用于实践,为患者解除病痛。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Thu Nov 08 14:19:05 CST 2018, time=2018-11-08, status=1, ipAttribution=)]
    2018-11-10 膀胱癌
  4. [GetPortalCommentsPageByObjectIdResponse(id=1638850, encodeId=2e33163885050, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Mar 29 22:51:00 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727708, encodeId=d9fa1e27708f6, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Jul 15 19:51:00 CST 2019, time=2019-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329171, encodeId=90ea13291e160, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sat Nov 10 03:51:00 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345382, encodeId=57e01345382e1, content=<a href='/topic/show?id=8907693e0fa' target=_blank style='color:#2F92EE;'>#生物标记#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69370, encryptionId=8907693e0fa, topicName=生物标记)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=278f2500221, createdName=12498fa0m11暂无昵称, createdTime=Sat Nov 10 03:51:00 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539212, encodeId=0fd015392124e, content=<a href='/topic/show?id=6505108534a' target=_blank style='color:#2F92EE;'>#lgE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10853, encryptionId=6505108534a, topicName=lgE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=beb613117181, createdName=HNYYM, createdTime=Sat Nov 10 03:51:00 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351954, encodeId=16f33519548c, content=好文,值得点赞!认真学习了,把经验应用于实践,为患者解除病痛。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Thu Nov 08 14:19:05 CST 2018, time=2018-11-08, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1638850, encodeId=2e33163885050, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Mar 29 22:51:00 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727708, encodeId=d9fa1e27708f6, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Jul 15 19:51:00 CST 2019, time=2019-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329171, encodeId=90ea13291e160, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sat Nov 10 03:51:00 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345382, encodeId=57e01345382e1, content=<a href='/topic/show?id=8907693e0fa' target=_blank style='color:#2F92EE;'>#生物标记#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69370, encryptionId=8907693e0fa, topicName=生物标记)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=278f2500221, createdName=12498fa0m11暂无昵称, createdTime=Sat Nov 10 03:51:00 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539212, encodeId=0fd015392124e, content=<a href='/topic/show?id=6505108534a' target=_blank style='color:#2F92EE;'>#lgE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10853, encryptionId=6505108534a, topicName=lgE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=beb613117181, createdName=HNYYM, createdTime=Sat Nov 10 03:51:00 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351954, encodeId=16f33519548c, content=好文,值得点赞!认真学习了,把经验应用于实践,为患者解除病痛。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Thu Nov 08 14:19:05 CST 2018, time=2018-11-08, status=1, ipAttribution=)]
    2018-11-10 HNYYM
  6. [GetPortalCommentsPageByObjectIdResponse(id=1638850, encodeId=2e33163885050, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Mar 29 22:51:00 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727708, encodeId=d9fa1e27708f6, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Jul 15 19:51:00 CST 2019, time=2019-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329171, encodeId=90ea13291e160, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sat Nov 10 03:51:00 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345382, encodeId=57e01345382e1, content=<a href='/topic/show?id=8907693e0fa' target=_blank style='color:#2F92EE;'>#生物标记#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69370, encryptionId=8907693e0fa, topicName=生物标记)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=278f2500221, createdName=12498fa0m11暂无昵称, createdTime=Sat Nov 10 03:51:00 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539212, encodeId=0fd015392124e, content=<a href='/topic/show?id=6505108534a' target=_blank style='color:#2F92EE;'>#lgE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10853, encryptionId=6505108534a, topicName=lgE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=beb613117181, createdName=HNYYM, createdTime=Sat Nov 10 03:51:00 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351954, encodeId=16f33519548c, content=好文,值得点赞!认真学习了,把经验应用于实践,为患者解除病痛。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Thu Nov 08 14:19:05 CST 2018, time=2018-11-08, status=1, ipAttribution=)]
    2018-11-08 1dd8a7c5m95(暂无匿称)

    好文,值得点赞!认真学习了,把经验应用于实践,为患者解除病痛。

    0

相关资讯

Allergy Asthma Immunol Res:屋尘螨敏感的老年人鼻炎患者中,舌下免疫治疗的效果和安全性评估

最近,有研究人员确定了屋尘螨(HDM)舌下免疫治疗(SLIT)在患有AR的老年人患者中治疗的效果和安全性。研究包括了45名年龄不小于60岁的HDM诱导的AR患者,并分为2个小组,分别为SLIT治疗组(n=30)和对照组(n=15)。研究发现,在人口统计特征,鼻黏膜总症状得分(STSS),皮肤对HDMs的反应或者对HDMs的血清总的/特异的lgE水平在2个小组之间均没有显著额差异。在第1年,2个小组

Immunotherapy:马齿苋库提取物舌下免疫治疗耐受性和阳性治疗效果研究

最近,有研究人员评估了马齿苋库提取物舌下免疫治疗在患有过敏性鼻窦炎患者的耐受性和治疗效果。研究包括了51名患者,并且进行马齿苋库提取物舌下免疫治疗(6次增加剂量),并且每月对治疗进行调查。研究发现,470给药剂量下,只有3.8%的患者消除了系统性反应(1.5%的非特异性,2.3%的为等级1)。考虑到研究的治疗效果参数,研究人员发现,最后一次的皮肤反应和基线时间点测量的皮肤反应相比,具有显著的降低,

盘点:鼻炎与治疗

【1】Expert Opin Pharmacother:苯磺酸贝托司汀在永久过敏性鼻炎中的治疗结果分析影响研究苯磺酸贝托司汀(BB)是二代H1抗组胺药物,作为一种滴眼液,在美国是通过FDA批准的可以用于过敏性结膜炎治疗的药物。在其他的国家,口服BB是广泛存在的,主要是用于过敏性鼻炎(AR)以及荨麻疹和慢性瘙痒症状的改善,并且与其他药物治疗的结果类似。最近,有研究人员对文献进行了综合的搜索,这些

秋季鼻炎 痛苦如“绝症”! 70岁呼吸科老主任教你一招破解

有一种疾病,我国不同程度的患病人群高达3亿人,相当于每4个人就有一个人在饱受折磨。那就是鼻炎。

Eur Ann Allergy Clin Immunol:移动应用apps在过敏性呼吸道疾病中的作用

最近,有研究人员对移动应用在过敏性呼吸道疾病中的作用进行了多中心的调查。他们研究的主要目的是调查在过敏性呼吸道疾病的控制和治疗过程中,移动应用apps的使用和效果情况。研究人员利用包括12个多选问题的调查问卷进行研究,并包括了360名参与者(153名男性和207名女性)。值得注意的是,290名参与者拥有移动手机。120名为个人电脑,68名为平板电脑。123名报道经常使用移动应用apps,209名为

盘点:鼻炎研究进展

鼻炎即鼻腔炎性疾病,是病毒、细菌、变应原、各种理化因子以及某些全身性疾病引起的鼻腔黏膜的炎症。鼻炎的主要病理改变是鼻腔黏膜充血、肿胀、渗出、增生、萎缩或坏死等。梅斯医学小编整理了近期过敏性鼻炎的研究进展,与大家一起分享学习!【1】J Agromedicine:美国农场经营者农药的使用、过敏性鼻炎和哮喘情况分析 最近,有研究人员在美国农场经营者中调查了特殊农药的使用与过敏性鼻炎以及哮喘